---
title: "MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292765644.md"
description: "On July 15, 2026, MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), disclosed that they have successfully reached the target enrollment of 200 patients in the SEANOBI-ALS study. This study, also known as Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS (NCT 06743776), is investigating the efficacy of MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS)."
datetime: "2026-07-15T12:02:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292765644.md)
  - [en](https://longbridge.com/en/news/292765644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292765644.md)
---

# MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

On July 15, 2026, MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), disclosed that they have successfully reached the target enrollment of 200 patients in the SEANOBI-ALS study. This study, also known as Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS (NCT 06743776), is investigating the efficacy of MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS).

### Related Stocks

- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)
- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)

## Related News & Research

- [MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target](https://longbridge.com/en/news/292763424.md)
- [Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign | NXTS Stock News](https://longbridge.com/en/news/294063569.md)
- [HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strong](https://longbridge.com/en/news/294357093.md)
- [Toto: Sales up, profits down; Advanced Ceramics and global growth offset Japan margin pressure](https://longbridge.com/en/news/294465360.md)
- [One Point's Peter Boockvar on what the yen moves could mean for global markets](https://longbridge.com/en/news/294422501.md)